CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow

Similar documents
Secondary Hyperparathyroidism: Where are we now?

CKD-MBD CKD mineral bone disorder

Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD)

HYPERPARATHYROIDIS M FAISAL GHANI SIDDIQUI MBBS; FCPS; PGDIP-BIOMEDICAL ETHICS; MCPS-HPE

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients

PRIMARY HYPERPARATHYROIDISM

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause

Persistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019

Case study Group 2 presentation

Contents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian

PARATHYROID, VITAMIN D AND BONE

Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management

2017 KDIGO Guidelines Update

The Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels

Clinical Guideline Bone chemistry management in adult renal patients on dialysis

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012

Sensipar. Sensipar (cinacalcet) Description

Sensipar (cinacalcet)

Chapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016

Awaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page

Guidelines and new evidence on CKD - MBD treatment

Therapeutic golas in the treatment of CKD-MBD

The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY

Treatment Options for Chronic Kidney

Metabolic Bone Disease (Past, Present and Future Challenges in the Management)

DR. DARWISH H. BADRAN. Parathyroid glands

Month/Year of Review: September 2012 Date of Last Review: September 2010

Cinacalcet treatment in advanced CKD - is it justified?

Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet:

Chronic Kidney Disease in Primary Care

Southern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism

Kobe University Repository : Kernel

Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis

New biological targets for CKD- MBD: From the KDOQI to the

Malnutrition and Role of Nutrition in BMD:CKD

Chronic Kidney Disease Mineral Bone Disease

Hyperphosphatemia is associated with a

Should cinacalcet be used in patients who are not on dialysis?

Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia

Hyperparathyroidism. When to Suspect, How to Diagnose, When and How to Intervene. Johanna A. Pallotta, MD, FACP, FACE

Metabolic Bone Disease Related to Chronic Kidney Disease

Level 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor

76 year-old female presents with muscle cramps. Jess Hwang 12/6/12

PRIMARY HYPERPARATHYROIDISM PRIMARY HYPERPARATHYROIDISM. Hyperparathyroidism Etiology. Common Complex Insidious Chronic Global Only cure is surgery

Management of CKD. Goce Spasovski, R. Macedonia

The Parathyroid Glands

25/10/56. Hypothyroidism Myxedema in adults Cretinism congenital deficiency of thyroid hormone Hashimoto thyroiditis. Simple goiter (nontoxic goiter)

Medicines for anaemia and mineral bone disease

Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD

Chronic Kidney Disease The 6 Pillars. Dr. Tiina Podymow Associate Professor Division of Nephrology McGill University Health Centre

Calcium metabolism and the Parathyroid Glands. Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands

The Skeletal Response to Aging: There s No Bones About It!

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.

Endocrine Regulation of Calcium and Phosphate Metabolism

CKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire

Posttransplant Bone Disease. Budapest 2007

Secondary hyperparathyroidism an Update on Pathophysiology and Treatment

chapter 1 & 2009 KDIGO

Secondary hyperparathyroidism in dialysis patients

Renal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young

Head and Neck Endocrine Surgery

Greater Manchester Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)

Magnesium Homeostasis

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes

Treatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia

2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary

Case 2: 30 yr-old woman with 7 yr history of recurrent kidney stones

PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL

Parathyroid Imaging. A Guide to Parathyroid Surgery

Velphoro (sucroferric oxyhydroxide)

Disclosure. Topic Outline. Calcium, Vitamin D, PTH Disorders. PTH/Calcium-Normal Physiology. I have nothing to disclose

The role of calcimimetics in chronic kidney disease

The Effectiveness and Cost-Effectiveness of Cinacalcet for the Treatment of Hyperparathyroidism Secondary to Impaired Renal Function

Month/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )

APPLYING KDIGO GUIDELINES TO

Literature Scan: Phosphate Binders

OPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura

Dana Lecture 2 Chronic Kidney Disease

Approach to a patient with hypercalcemia

See Important Reminder at the end of this policy for important regulatory and legal information.

CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)

Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients

Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):

Hyperparathyroidism. There is however another more potent method to achieve the lowering of PTH in a more natural way.

PHARM NOTES. Neil Medical Group: The Leading Pharmacy Provider in the Southeast. Neil Medical Group: The Leading. Hyperparathyroidism: An Overview

Case Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy

Parathyoid glands and PTH

The hart and bone in concert

Parathyroid hormone (serum, plasma)

Parsabiv (etelcalcetide) NEW PRODUCT SLIDESHOW

Disclosures. Topics. Staging and GFR. K-DOQI Staging of Chronic Kidney Disease. Definition of Chronic Kidney Disease. Chronic Kidney Disease

44 yo man with hypercalcemia. Katie Stanley, MD August 9, 2012

Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials

Transcription:

CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow

CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker of kidney damage: ACR 30 mg/g Urine sediment abnormalities Electrolyte and other abnormalities due to tubular disorders Abnormalities detected by histology Structural abnormalities (imaging) History of kidney transplant OR GFR < 60

Parathyroid glands 4 glands behind thyroid in front of neck

Parathyroid physiology

Parathyroid hormone Normal circumstances PTH: Increases calcium Lowers PO4 (the renal excretion outweighs the bone release and gut absorption) Increases Vitamin D Controlled by feedback Low Ca and high PO4 increase PTH High Ca and low PO4 decrease PTH

In renal disease: Gets all messed up! Decreased phosphate clearance: High Po4 Low 1,25 OH vitamin D = Low Ca Phosphate binds calcium = Low Ca Low calcium, high phosphate, and low VitD all feedback to cause more PTH release This is referred to as secondary hyperparathyroidism Usually not seen until GFR < 45

Who cares Chronically high PTH High bone turnover = renal osteodystrophy Osteoporosis/fractures Osteomalacia Osteitis fibrosa cystica High phosphate Associated with faster progression CKD Associated with higher mortality Calcium-phosphate precipitation Soft tissue, blood vessels (eg: coronary arteries) Low 1,25 OH-VitD Immune status, cardiac health?

KDIGO KDIGO: Kidney Disease Improving Global Outcomes Most recent update regarding Mineral and bone disorders was 2017, previous guidelines were in 2009

So what can we do? KDIGO Monitor serum Ca, PO4, PTH, ALP at least once once GFR < 60 (Stage 3a) Frequency of measurement depends on CKD stage (q1-6 months)

Phosphate KDIGO 2017: Suggest lowering phosphate towards the normal range Practically we tend to target PO4 level of 1.1 1.8 mmol/l in patients with very low GFR

Phosphate DIET!!! Phosphate binders Calcium based 1 st line (cheaper) Calcium carbonate or Calcium acetate Max 1.5 g/day elemental calcium Acetate lower calcium load Non-calcium based ($), 2 nd line Use when hypercalcemic or calcium load too high Evidence of reduced coronary calcification Sevelamer (renagel) Lanthinum?safety KIDGO recommends avoiding aluminum containing binders

Calcium Guidelines basically suggest avoiding hypercalcemia Avoid high doses of calcium binders

PTH The optimal level of PTH is not clear in CKD Treat reversible causes (low Ca, high PO4) in progressively rising PTH In CKD5 we generally target level 2-9x the upper limit of normal (Normal =8-9 pmol/l) Based on CSN 2006 guidelines CKD patients should have a higher expected PTH Basically want to avoid having it too high or too low (both can cause problems)

PTH First line: Treatment of high PO4 and low Calcium If still high, add activated vitamin D Alfacalcidol (one-alpha) Calcitriol (if liver failure) Can use cinacalcet or parathyroidectomy in difficult to control disease (this typically occurs in end stage renal disease)

Vitamin D

Some other tidbits

Primary hyperparathyroidism Parathyroid adenoma or hyperplasia

Primary hyperparathyroidism Parathyroid adenoma causes excess PTH secretion Not responsive to negative feedback High PTH, High Calcium, Low phosphate Different from secondary in renal failure where you get high phosphate and low calcium Requires surgical intervention

Primary hyperparathyroidism We do see this this in our CKD patients and catching it is important Some clues: PTH higher than expected for level of GFR, calcium high, phosphate low

Tertiary hyperparathyroidism In the setting of renal failure and prolonged secondary hyperparathyroidism Chronic stimulation of parathyroid gland leads to hyperplasia, and autologous PTH secretion +++ PTH, High Ca, High PO4 Severe bone disease Needs surgery Sometimes can be medically managed (cinacalcet)

Questions??